Fiche centre
Vanderbilt Medical Center
Nashville — United States
Essais liés5clinical trials
VilleNashvillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05069558
Essais cliniques associés
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| Investigational PFO Closure Device | Accident vasculaire cérébral | Non applicable | NCT05069558 | OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | ACTIVE_NOT_RECRUITING |
| Device Implantation- Boston Scientific, VERCISE GENUS™ system | Alzheimer | Non applicable | NCT05882344 | Cholinergic Deep Brain Stimulation for Alzheimer's Disease | ENROLLING_BY_INVITATION |
| BIA 28-6156 | Parkinson | À vérifier | NCT07522606 | Compassionate Use for BIA 28-6156 in Patients With Parkinson's Disease (PD) Who Have a Pathogenic Variant in the GBA1 Gene (GBA-PD) and Completed the ACTIVATE Study | NO_LONGER_AVAILABLE |
| Atogepant 60 mg | Migraine | Phase 4 | NCT06972056 | Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study | RECRUITING |